chenxu

Chenxu (Shanghai) Biotechnology is a Chinese biotechnology company specializing in early-stage drug discovery and medicinal chemistry services. Founded in 2016, the company leverages a proprietary platform integrating high-throughput screening and chemical proteomics to identify novel therapeutic targets and small molecule candidates. Chenxu maintains an internal pre-clinical pipeline primarily focused on oncology, with active programs targeting tumor-related membrane proteins and E3 ligases for protein degradation. In addition to its proprietary research and development, the company operates as a contract research organization (CRO), providing custom synthesis and lead optimization services to global pharmaceutical and biotech partners. Chenxu is actively seeking external partnerships for the co-development and licensing of its early-stage oncology assets.